Advertising

Bristol Myers Squibb

BMY-N

NYSE:BMY

68.34
0.38 (0.56%)
Bristol-Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, ...
More at Wikipedia

Analysis and Opinions about BMY-N

Signal
Opinion
Expert
Chart
COMMENT
COMMENT
April 16, 2021
They report Friday. He likes the CEO, but isn't sure if this stock can break from the pack.
Show full opinionHide full opinion
They report Friday. He likes the CEO, but isn't sure if this stock can break from the pack.
Jim Cramer - Mad Money
Price
$65.460
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 17, 2021
(A Top Pick Jan 22/20, Down 8%) Sexier areas of the market pulled money away from the boring companies. Over the next decade, sees a fantastic R&D pipeline of cancer drugs. Tremendous cashflow will be deployed in R&D and acquisitions to augment their growth profile. Stick with it to collect the dividend with some slow growth.
Show full opinionHide full opinion
(A Top Pick Jan 22/20, Down 8%) Sexier areas of the market pulled money away from the boring companies. Over the next decade, sees a fantastic R&D pipeline of cancer drugs. Tremendous cashflow will be deployed in R&D and acquisitions to augment their growth profile. Stick with it to collect the dividend with some slow growth.
James Telfser
Price
$60.535
Owned
Yes
HOLD
HOLD
February 11, 2021

Diversified large cap. A lot of businesses working really well. Celgene acquisition diversified their oncology. Main drug is performing well. Trading at 8.5x forward earnings, with low double digit EPS growth. One of his core holdings.

Show full opinionHide full opinion

Diversified large cap. A lot of businesses working really well. Celgene acquisition diversified their oncology. Main drug is performing well. Trading at 8.5x forward earnings, with low double digit EPS growth. One of his core holdings.

Paul MacDonald
Price
$59.950
Owned
Yes
BUY
BUY
January 11, 2021

It was up nearly 4% today during JPMorgan's healthcare conference. BMY delivered good news. Management announced strong early revenue goals for new products, including three new drugs that could hit $4 billion in sales this decade. Their strong pipeline of drugs was bulked by buying Celgene and MyoKardia. They also announced a bullish free cash-flow forecasts for coming years which will buyback shares and pay down debt. For years, this has failed to break out from mid-$60s, but that could change.

Show full opinionHide full opinion

It was up nearly 4% today during JPMorgan's healthcare conference. BMY delivered good news. Management announced strong early revenue goals for new products, including three new drugs that could hit $4 billion in sales this decade. Their strong pipeline of drugs was bulked by buying Celgene and MyoKardia. They also announced a bullish free cash-flow forecasts for coming years which will buyback shares and pay down debt. For years, this has failed to break out from mid-$60s, but that could change.

TOP PICK
TOP PICK
October 20, 2020

He liked their Celgene acquisition last year (though the market didn't), because it diversified their exposure to other drugs which have exectued well. Their R&D and core business are doing well. The stock trades at only 8x earnings. There is a disconnect between company performance and the market. It's very cheap and they execute well. (Analysts’ price target is $72.93)

Show full opinionHide full opinion

He liked their Celgene acquisition last year (though the market didn't), because it diversified their exposure to other drugs which have exectued well. Their R&D and core business are doing well. The stock trades at only 8x earnings. There is a disconnect between company performance and the market. It's very cheap and they execute well. (Analysts’ price target is $72.93)

Paul MacDonald
Price
$60.990
Owned
Yes
TOP PICK
TOP PICK
October 6, 2020
Stockchase Research Editor: Michael O'Reilly This household pharma player has just made a $13 billion acquisition of a company that focuses on the treatment of irregular heart rhythms -- something that doesn't have another treatment option yet. This will go to diversify the company's success in the cancer treatment field. With an outlook to earnings growth of over 17% next year the Price to Earnings Growth Ratio is just 1.1 -- suggesting good value at these levels. We would trade this with a $54 stop-loss. Yield 3.04% (Analysts’ price target is $73.62)
Show full opinionHide full opinion
Stockchase Research Editor: Michael O'Reilly This household pharma player has just made a $13 billion acquisition of a company that focuses on the treatment of irregular heart rhythms -- something that doesn't have another treatment option yet. This will go to diversify the company's success in the cancer treatment field. With an outlook to earnings growth of over 17% next year the Price to Earnings Growth Ratio is just 1.1 -- suggesting good value at these levels. We would trade this with a $54 stop-loss. Yield 3.04% (Analysts’ price target is $73.62)
TOP PICK
TOP PICK
October 5, 2020
There is so much value in drug companies. His model price is $111, or a 90% upside on this one. It may be suffering a little from maybe Biden winning the election. It pays 3% while interest rates are zero. There is not much downside. (Analysts’ price target is $72.79)
Show full opinionHide full opinion
There is so much value in drug companies. His model price is $111, or a 90% upside on this one. It may be suffering a little from maybe Biden winning the election. It pays 3% while interest rates are zero. There is not much downside. (Analysts’ price target is $72.79)
Brian Acker, CA
Price
$59.200
Owned
Yes
BUY
BUY
October 5, 2020

MyoKardia deal: https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash Today BMY announced it's buying MyoKardia (MYOK-Q) ifor US$13.1 billion cash. MyoKardia makes drugs to fight heart disease and heart conditions, including mavacamten, a drug for which they will file an application in Q1-2021. The stock has gotten really cheap. He loves this deal.

Show full opinionHide full opinion

MyoKardia deal: https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash Today BMY announced it's buying MyoKardia (MYOK-Q) ifor US$13.1 billion cash. MyoKardia makes drugs to fight heart disease and heart conditions, including mavacamten, a drug for which they will file an application in Q1-2021. The stock has gotten really cheap. He loves this deal.

Jim Cramer - Mad Money
Price
$59.200
Owned
Unknown
TOP PICK
TOP PICK
July 10, 2020
He has a model price over $111 -- a 95% upside opportunity. Yield 3.13% (Analysts’ price target is $66.94)
Show full opinionHide full opinion
He has a model price over $111 -- a 95% upside opportunity. Yield 3.13% (Analysts’ price target is $66.94)
Brian Acker, CA
Price
$57.430
Owned
Yes
DON'T BUY
DON'T BUY
February 5, 2020
They are focused on the drug side of health care. There is a lot pressure on costs and from a political perspective as well. The company has had a great run as of late, but drugs can be very volatile. He generally favors the equipment and insurance sectors in health care.
Show full opinionHide full opinion
They are focused on the drug side of health care. There is a lot pressure on costs and from a political perspective as well. The company has had a great run as of late, but drugs can be very volatile. He generally favors the equipment and insurance sectors in health care.
Zachary Curry
Price
$65.490
Owned
No
TOP PICK
TOP PICK
January 22, 2020

A leading oncology drug producer, trading at 10x earnings and paying a 3% dividend. Many catalysts are coming. They merged with Celgene, a deal which has raised investor expectations, with potentially strong synergies. This could trade at 11x earnings. You can make 20% on this. Holding a healthcare name is key. (Analysts’ price target is $71.64)

Show full opinionHide full opinion

A leading oncology drug producer, trading at 10x earnings and paying a 3% dividend. Many catalysts are coming. They merged with Celgene, a deal which has raised investor expectations, with potentially strong synergies. This could trade at 11x earnings. You can make 20% on this. Holding a healthcare name is key. (Analysts’ price target is $71.64)

James Telfser
Price
$67.430
Owned
Yes
COMMENT
COMMENT
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Show full opinionHide full opinion
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Bruce Murray
Price
$57.600
Owned
No
COMMENT
COMMENT
October 16, 2019

They're getting a good deal on Celgene. Can't say what he'll do with this stock, but BMY is attractive.

Show full opinionHide full opinion

They're getting a good deal on Celgene. Can't say what he'll do with this stock, but BMY is attractive.

Ashley Misquitta, CFA
Price
$51.510
Owned
Unknown
DON'T BUY
DON'T BUY
October 4, 2019
It is a complex business with patents that come off, rising class-action lawsuits and rising regulatory threat politically in the US. He views it as a politically vulnerable industry and would suggest there are better things to buy. (Analysts’ price target is $59.00)
Show full opinionHide full opinion
It is a complex business with patents that come off, rising class-action lawsuits and rising regulatory threat politically in the US. He views it as a politically vulnerable industry and would suggest there are better things to buy. (Analysts’ price target is $59.00)
David Baskin
Price
$50.750
Owned
No
COMMENT
COMMENT
September 27, 2019

Bristol Myers's latest drugs haven't done as well as they thought. GSK has refocused into pharmaceuticals, and they sold off the consumer products division. After 5 years, they have both come to be around the same price. He would prefer GSK.

Show full opinionHide full opinion
Bristol Myers Squibb (BMY-N)
September 27, 2019

Bristol Myers's latest drugs haven't done as well as they thought. GSK has refocused into pharmaceuticals, and they sold off the consumer products division. After 5 years, they have both come to be around the same price. He would prefer GSK.

Gavin Graham
Price
$50.220
Owned
Unknown
Showing 1 to 15 of 165 entries

Bristol Myers Squibb(BMY-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Bristol Myers Squibb is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bristol Myers Squibb(BMY-N) Frequently Asked Questions

What is Bristol Myers Squibb stock symbol?

Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N

Is Bristol Myers Squibb a buy or a sell?

In the last year, 4 stock analysts published opinions about BMY-N. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.

Is Bristol Myers Squibb a good investment or a top pick?

Bristol Myers Squibb was recommended as a Top Pick by Jim Cramer - Mad Money on 2021-04-16. Read the latest stock experts ratings for Bristol Myers Squibb.

Why is Bristol Myers Squibb stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bristol Myers Squibb worth watching?

4 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.

What is Bristol Myers Squibb stock price?

On 2021-07-23, Bristol Myers Squibb (BMY-N) stock closed at a price of $68.34.